. 2019 Feb 26;10(1):35–45. doi: 10.14740/wjon1179

Table 3. Baseline Characteristics of Squamous Cell Carcinoma.

	All	LIPI			P
	All	Good	Intermediate	Poor	P
N	110	61	39	10
Backgrounds
Sex (N), male/female	85/25	49/12	28/11	8/2	0.59^a
Age (years), median (IQR)	71.5 (65 - 76)	72 (65 - 76)	70 (66 - 75)	71.5 (62 - 75)	0.62^b
Smoking status, non/former /current smoker	8/42/60	4/19/38	3/20/16	1/3/6	0.23^a
PD-L1 status, ≥ 50%/1-49% /< 1%/NA	1/1/2/106	1/0/1/59	0/1/1/37	0/0/0/22	1.00^a
ECOG-PS, 0-1/≥ 2	83/27	50/11	28/11	5/5	0.08^a
Stage, IIIB/IV/recurrence	40/57/13	25/25/11	14/23/2	1/9/0	0.03^a
Metastatic sites, ≥ 2	33	16	13	4	0.52^a
First-line chemotherapy
Regimen
Single/combination (N)	11/89	8/53	2/37	1/9	0.39^a
PTX or nab-PTX	72	36	28	8	0.29^a
Efficacy
ORR (%) (95% CI)	42.7 (33.3 - 52.5)	45.9 (33.1 - 59.2)	35.9 (21.2 - 52.8)	50.0 (18.7 - 81.3)	0.60^a
DCR (%) (95% CI)	65.5 (55.8 - 74.3)	63.9 (50.6 - 75.8)	69.2 (52.4 - 83.0)	60.0 (26.2 - 87.8)	0.79^a
Second and further line
Second-line (N)	66	39	23	4	0.34^a
Immuno-checkpoint inhibitor (N)	10	5	5	0	0.61^a
Laboratory data
dNLR
Median (IQR)	2.25 (1.73 - 3.13)	2.00 (1.69 - 2.39)	3.20 (1.88 - 4.04)	3.39 (3.19 - 3.91)	< 0.01^b
≥ 3 (N)	30	0	20	10	< 0.01^a
LDH
Median (IQR)	198.5 (168 - 229)	181 (158 - 202)	224 (189.5 - 277.5)	282 (243 - 304.5)	< 0.01^b
> ULN	29	0	19	10	< 0.01^a

CI: confidence interval; DCR: disease control rate; dNLR: derived neutrophil-to-lymphocyte ratio; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; IQR: interquartile range; LDH: lactate dehydrogenase; LIPI: lung immune prognostic index; NA: not assessed; nab-PTX: nanoparticle albumin-bound paclitaxel; ORR: overall response rate; PTX: paclitaxel; ULN: upper limit of normal. ^aFisher’s exact test; ^bKruskal-Wallis rank sum test.